Riik: Iirimaa
keel: inglise
Allikas: HPRA (Health Products Regulatory Authority)
PODOPHYLLUM RESIN SALICYLIC ACID
Norgine Limited
20/25 %w/w
Ointment
1983-04-01
IRISH MEDICINES BOARD ACT 1995, AS AMENDED MEDICINAL PRODUCTS (CONTROL OF PLACING ON THE MARKET) REGULATIONS, 2007, AS AMENDED PA0102/017/001 Case No: 2043376 The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to NORGINE LIMITED CHAPLIN HOUSE, WIDEWATER PLACE, MOORHALL ROAD, HAREFIELD, UXBRIDGE, MIDDLESEX UB9 6NS, UNITED KINGDOM an authorisation, subject to the provisions of the said Regulations, in respect of the product POSALFILIN OINTMENT the particulars of which are set out in the attached Schedule. The authorisation is also subject to the general conditions as may be specified in the said Regulations as listed on the reverse of this document. This authorisation, unless previously revoked, shall continue in force from 01/04/2008. Signed on behalf of the Irish Medicines Board this ________________ A person authorised in that behalf by the said Board. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 15/06/2010_ _CRN 2043376_ _page number: 1_ PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Posalfilin Ointment 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 10 g tube of POSALFILIN Ointment contains 20% w/w Podophyllum Resin and 25% w/w Salicylic Acid. For excipients, see 6.1. 3 PHARMACEUTICAL FORM Dark brown opaque ointment with a characteristic odour. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For the treatment of plantar warts. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _ADULTS (INCLUDING THE ELDERLY) AND CHILDREN_: A corn ring should be placed around the wart, cutting the ring to fit if necessary. A minimal amount of ointment should be applied to the exposed wart, taking care to avoid norma Lugege kogu dokumenti